Tetraphase’s second PhIII for its lead antibiotic fails in a repeat setback for UTIs
Tetraphase $TTPH is 0 for 2 in Phase III studies of its IV antibiotic eravacycline for complicated urinary tract infections.
Researchers for the biotech say …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
